Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Solithromycin Proves Safe, Makes Cempra A Deal Target

This article was originally published in The Pink Sheet Daily

Executive Summary

The antibiotic showed promising results in a late-stage study of the oral formulation, setting the company up as a potential target for acquirers and partnering opportunities – though for now it is signaling its intent to go it alone.

You may also be interested in...



Cempra Details Launch Plans For Solithromycin

Expecting approval for CABP before the end of 2016, Cempra says solithromycin will offer a significant treatment-resistance edge over the earlier macrolide antibiotic azithromycin.

BARDA To Fund Pediatric Development Of Cempra’s Solithromycin

Antibiotic-focused biotech can earn $58 million over five years under the government contract, which provides for testing of the novel macrolide in pediatric indications and for protection against bioterror-threat pathogens.

Panel Gives Mixed Reviews To Using Single Trial For Community-Acquired Pneumonia

The Anti-Infective Drugs Advisory Committee's failure to agree on a preferred approval pathway for antibiotics to treat community-acquired bacterial pneumonia opens the door for FDA to offer several options to industry.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS077845

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel